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Abstract 
 
Purpose: In the randomized G-PCNSL-SG-1 trial, the addition of whole brain radiotherapy (45 Gy) to high-
dose methotrexate (HD-MTX)-based chemotherapy (early WBRT arm) did not prolong overall survival (OS) as 
compared to HD-MTX-based chemotherapy alone (no early WBRT arm) in primary CNS lymphoma (PCNSL) 
patients. To determine whether WBRT might lead to quality of life (QoL)-relevant late neurotoxicity, this trial 
prospectively monitored QoL.  
Methods: QoL measurements were performed using the EORTC-QLQ-C30 and BN20 questionnaires and 
combined with repeated Mini Mental State Examinations (MMSE). Exploratory data analysis included the 318 
patients in the per-protocol population.  
Results: In year 2 after randomization, cognitive functioning and global health status were reduced in the early 
WBRT arm as compared to the no early WBRT arm (p=0.004 and p=0.022, respectively). Also, fatigue 
(p=0.037), appetite loss (p=0.006) and hair loss (p=0.002) were more intense in the early WBRT arm. MMSE 
testing revealed lower values (p=0.002) in the early WBRT arm. A mixed model analysis of longitudinal data 
additionally showed differences favouring the no early WBRT arm in 15 of 26 dimensions of QoL. 
Conclusions: The analysis of subjective QoL questionnaires and objective MMSE testing revealed that QoL 
and cognition were conserved in the arm without early WBRT. Thus, even though it was an exploratory 
analysis, the results of G-PCNSL-SG1 challenge the place of WBRT in the primary therapy of PCNSL. 
 
Keywords: Primary CNS lymphoma, whole brain radiotherapy, quality of life, cognition, high-dose 
methotrexate 
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Introduction 
The outcome of patients with primary CNS lymphoma (PCNSL) has greatly improved: With high-dose 
methotrexate (HD-MTX)-based chemotherapy as backbone of all efficient therapies, survival has increased and, 
at least in younger patients, long-term survival can be achieved in a significant proportion of patients (Korfel 
and Schlegel 2013). It remains a major point of discussion whether whole brain radiotherapy (WBRT) should be 
part of primary therapy. The G-PCNSL-SG-1 non-inferiority trial addressed this question by randomizing 
WBRT as compulsory part of first-line therapy (early WBRT) against its omission from first-line therapy (no 
early WBRT; Fig 1). As the main result, G-PCNSL-SG1 did not find significant differences in overall survival 
(OS) between the two arms although the non-inferiority of the no early WBRT arm could not be formally 
proven (Thiel et al. 2010; Korfel et al. 2015).  
 
The application of WBRT in combination with HD-MTX-based chemotherapy was associated with late 
neurotoxicity including progressive cognitive decline in a substantial proportion of patients, particularly the 
elderly in non-comparative trials (Correa et al. 2004; Harder et al. 2004; Herrlinger et al. 2005; Correa et al. 
2012). G-PCNSL-SG1 was the first randomized trial prospectively collecting and evaluating data of QoL and 
cognition.   
  
5 
 
Material and Methods 
 
Patient population, randomization and treatment  
From 2000 to 2009, G-PCNSL-SG-1 recruited adult immunocompetent patients with newly diagnosed, 
histologically confirmed PCNSL. A Karnofsky performance score (KPS) of less than 50 unrelated to PCNSL or 
less than 30 due to PCNSL was an exclusion criteria. Patients were unblindedly randomized 1:1 for HD-MTX-
based chemotherapy + WBRT vs. HD-MTX-based chemotherapy without primary WBRT (Fig 1). The 
comprehensive list of all inclusion/exclusion criteria and details on randomization have been published (Thiel et 
al. 2010). The trial (ClinicalTrials.gov number NCT00153530) was approved by all local ethics committees, all 
patients gave their written informed consent.  
 
Treatment included 6 biweekly courses of HD-MTX (4 g/m2, 4 h intravenous infusion). If glomerular filtration 
rate (GFR) was below 1.67 ml/s, MTX dose was reduced by the percentage that the GFR was below 1.67 ml/s. 
Patients with GFR <0.83 ml/s were excluded. After enrolment of 409/551 patients all further patients received 
additional ifosfamide 1.5 g/m2 (daily, day 3-5). Therapeutic decisions after 6 courses were made according to 
the restaging results and the randomization result obtained at the time of study inclusion (Fig 1): Patients in 
complete response (CR) received either WBRT (45 Gy in 1.5 Gy daily fractions) as consolidation therapy (early 
WBRT arm) or were followed without any further primary therapy (no early WBRT arm); patients without CR 
received either WBRT (early WBRT arm) or high-dose cytarabine (no early WBRT arm; 2x 3 g/m2 per day for 
2 days every three weeks). All patients were to be followed with neurological examination, contrast-enhanced 
MRI, quality of life QoL assessments and Mini Mental State Examinations (MMSE) every 3 months (first year), 
4 months (year 2) or 6 months (starting from year 3).  
 
As shown in the previously published CONSORT statement (Thiel et al. 2010), 318 out of 551 patients 
randomized upfront received the treatment specified by randomization and were thus included in the per 
protocol population. To most accurately define the effects of WBRT and to account for the substantial number 
of patients not receiving their assigned treatment, the present analysis of QoL and MMSE is restricted to the per 
protocol population.  
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QoL and MMSE analysis 
QoL was an exploratory secondary endpoint and was determined using the EORTC self-reporting questionnaires 
EORTC-QLQ-C30 and EORTC-QLQ-BN20 [8,9]. EORTC-QLQ-C30 includes 30 items regarding general 
aspects of QoL of cancer patients. EORTC-QLQ-BN20 adds 20 items addressing brain-specific questions. 
Responses were scored, analyzed, and transformed to a 0-100 scale (Fayers et al. 1999). For functional scores a 
higher score is favourable, while for symptom scores higher scores indicating higher symptom burden is 
unfavourable. Although nowadays not regarded as the standard for neurocognitive testing when looking for 
neurotoxic sequelae of cancer therapies, the study protocol originating from the year 2000 specified that 
cognition was measured using the MMSE (Folstein et al. 1975). MMSE is a paper and pencil test summarizing 
different cognitive domains and providing an overall result on a 30 points scale.  
 
The patients were asked to complete the QoL questionnaires and MMSE at baseline and subsequently at every 
clinical and imaging follow-up examination until death. Thus, QoL data were obtained irrespective of disease 
progression. To determine the development of QoL and MMSE over time, median values for QoL and MMSE 
scores were determined for the following time intervals: up to day 20 after randomization (baseline), day 21-365 
(year 1), day 366-730 (year 2), day 731-1095 (year 3), and day 1096-1460 (year 4). If several data points per 
time interval were available for a particular score, the latest data point obtained was included in the analysis. 
Differences in QoL and MMSE between the arms in year 2 were analyzed for statistical significance using the 
Mann-Whitney-U test.  
 
Additionally, a linear mixed model analysis for the change of QoL and MMSE scores over time was performed. 
This analysis models the dependence of repeated measurements over time by including a random effect for the 
patient. This analysis was carried out irrespective of tumor progression, i.e. values obtained after tumor 
progression were also included. For each QoL dimension a mean change/year in relation to pretherapeutic 
baseline levels was calculated. The development of the QoL scores in the two arms was compared to each other 
by testing for time*treatment interaction. Since this analysis was purely explorative, there was no correction for 
multiple testing.  
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Results 
 
Patients’ characteristics and QoL functional scores 
The details of patients’ characteristics in the per-protocol population used for analysis have already been 
reported (Thiel et al. 2010) and again summarized in Table 1. There were no apparent differences between the 
early WBRT and the no early WBRT arm regarding age, initial KPS, global health status and initial MMSE 
(Table 1) at baseline.  
 
QoL: Functional scores 
QoL functional scores were evaluated for six dimensions: global health status, physical functioning, role 
functioning, emotional functioning, social functioning and cognitive functioning. Figure 2A (global health 
status, emotional functioning, social functioning and cognitive functioning) and supplementary figure 1A 
(physical functioning and role functioning) show the development of these functional scores in the two 
randomization arms over time. The percentage of surviving patients providing data for these evaluations was 
45% (70 of 156 patients alive) in year 2, 38% (42 of 110 patients alive) in year 3 and 29% (20 of 68 patients 
alive) in year 4. In year 2 after randomization, cognitive functioning and global health status were reduced in 
early WBRT patients as opposed to patients without early WBRT. The patients evaluable for QoL in year 2 did 
not show evident differences between the two randomization arms regarding prognostically relevant parameters 
such as age distribution or KPS (Table 1). For both timepoints, baseline and year 2, OS of patients analyzable 
for QoL did not differ between the arms (Supplementary figure 2). In year 3 and 4 after randomization, median 
QoL scores in the early WBRT group remained below the median scores in the no early WBRT group (Fig 2A) 
but, with a small data base and the majority of patients not reporting QoL data, differences may not be 
overestimated.  
 
Median scores for emotional functioning and social functioning (Fig 2A) were lower in the early WBRT group 
than in the no early WBRT group at all follow-up time points. The differences did not reach statistical 
significance. For physical functioning and role functioning (Supplementary figure 1A), no differences between 
the treatment groups were found.  
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QoL: Symptom scores 
Figure 2B (communication deficit, fatigue, appetite loss, hair loss) and supplementary figure 1B (diarrhea, 
nausea and vomiting, insomnia, constipation, dyspnea, financial difficulties, pain, future uncertainty, motor 
dysfunction, visual dysfunction, bladder control, drowsiness, headaches, itchy skin, seizures, weakness of legs) 
show the development of symptom scores in the two study arms in the years after randomization. Three of the 
twenty symptom scores in the EORTC questionnaires showed differences in favour of the no early WBRT 
group at 2 years after randomization: fatigue, appetite loss, hair loss (Fig 2B). Borderline significance was found 
for differences in communication deficit (p=0.07). In year 4, no differences between the treatment groups were 
found any longer regarding the communication deficit and hair loss score (Fig 2B). As observed for the 
functional scores, there was a tendency for a lower symptom burden in the no early WBRT group in some 
symptom scores (Fig 2B and Supplementary figure 1B).  
 
Longitudinal mixed model analysis for functional and symptom scores 
A linear mixed model analysis for mean changes of QoL over time in comparison to pretherapeutic baseline was 
performed for all 26 QoL dimensions of the EORTC questionnaires. QoL was superior in the no early WBRT 
arm: differences in favour of the no early WBRT arm were found for 15 of 26 dimensions: physical functioning, 
role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, pain, insomnia, 
appetite loss, future uncertainty, visual disorder, communication deficit, drowsiness, itchy skin and weakness of 
legs. In none of the 26 dimensions a superiority of the early WBRT arm was seen.  
 
MMSE analysis 
At baseline, there were no overt differences between the early WBRT and the no early WBRT group regarding 
age and initial KPS. In year 2 after randomization, global cognition as determined by MMSE was worse in the 
early WBRT group as opposed to the no early WBRT group (Fig 2C, p=0.002). In years 3 and 4, the median 
MMSE in the no early WBRT group remained higher than in the early WBRT. While in year 2, 45% (70/156) 
patients had a MMSE test result, the absolute number of evaluable patients dropped during year 3 (47/109 
patients (43%)) and year 4 (23/68 patients alive (34%)). The mixed model analysis showed that with no early 
WBRT the MMSE score slightly improved by 0.27/year on a 30 point scale while in the early WBRT group, the 
mean change per year was -0.06 (p=0.13).  
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Discussion 
G-PCNSL-SG-1 trial is the first PCNSL trial documenting a negative influence of early WBRT on QoL 
parameters in a prospective, randomized setting. Importantly, the QoL domains related to neuropsychological 
deficits are most affected in year 2 after randomization (irrespective of progression), cognitive functioning was 
apparently reduced and fatigue was obviously increased in the early WBRT arm. This finding is also supported 
by a linear mixed model analysis. The changes in these and many other QoL domains may be highly relevant for 
the daily life of these patients since in year 2 after randomization, global health/overall quality of life was also 
reduced in the early WBRT arm.  
 
Subjective impairments in cognitive functioning documented in QoL analyses were mirrored by lower scores in 
the MMSE. The negative influence of WBRT on MMSE test scores may be underestimated since MMSE is 
relatively insensitive to the cluster of symptoms associated with late neurotoxicity, i.e. attention and 
concentration deficits (Meyers and Wefel 2003). This may contribute to the fact that median MMSE values 
found in G-PCNSL-SG-1 are relatively high between 26 and 29/30 achievable points (Fig 2C). Nevertheless, 
clear differences between the treatment groups were evident in year 2 after randomization. The higher rates of 
cognitive dysfunction observed with early WBRT is consistent with previous non-randomized observational 
studies showing a high rate of cognitive deficits and/or impaired QoL after HD-MTX followed by WBRT 
(Correa et al. 2004; Harder et al. 2004; Herrlinger et al. 2005; Correa et al. 2012; Ekenel et al. 2008) while 
neither QoL impairment nor neuropsychological deficits were found in 21 long-term survivors treated with 
chemotherapy alone (Juergens et al. 2010). Also, a non-randomized analysis of cognitive functioning and QoL 
in PCNSL long-term survivors treated with our without WBRT suggests that the addition of WBRT increases 
the risk of neurotoxicity (Doolittle et al. 2013). 
 
We are aware of the suboptimal data structure of our analysis, in particular caused by the low return rates of 
questionnaires. Nevertheless, to our knowledge, prospectively collected Qol data in a phase III trial evaluating 
the role of consolidating WBRT in primary therapy of PCNSL patients is not available elsewhere. Thus, the 
results presented here might still be helpful for determining whether WBRT has a place in primary treatment of 
PCNSL. The prolongation of progression-free survival induced by WBRT in the G-PCNSL-SG-1 trial may be 
an argument in favour of WBRT in primary therapy. However, the G-PCNSL-SG-1 trial also showed no 
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differences in overall survival between the groups (Thiel et al. 2010; Korfel et al. 2015). Now the present data 
show that  some dimensions of quality of life and in particular the cognitive performance in the lifetime 
remaining are reduced in patients receiving consolidating WBRT. Thus, a beneficial effect of WBRT beyond 
PFS prolongation cannot be detected. One could argue that HD-MTX with or without ifosfamide applied here is 
not sufficient to induce an in-depth remission which only would allow additional WBRT to be truly 
consolidating and survival-prolonging. Only with a more complex chemotherapy e.g. including rituximab, high-
dose cytarabine, thiotepa, and/or high-dose chemotherapy with stem cell rescue a remission could be achieved 
that allows WBRT to exert its full survival-prolonging potential (Ferreri et al. 2009; Illerhaus et al. 2006). So 
far, there is no data supporting such a theoretical concept in PCNSL and therefore it appears to be reasonable to 
omit neurotoxic WBRT in the form it was given in the G-PCNSL SG1 trial (45 Gy in 1.5 Gy fractions) from 
primary HD-MTX-based therapy on the basis of the G-PCNSL-SG-1 data. This is even more prudent since the 
combination of WBRT with a more intense chemotherapy than HD-MTX alone has the potential to be even 
more neurotoxic.  
 
In the G-PCNSL-SG-1 trial as well as in published case series, WBRT was applied with a comparably high total 
dose of 45 Gy, but with decreased single fractions of 1.5 Gy (Thiel et al. 2010; Correa et al. 2012). One way to 
reduce the risk of neurotoxicity could be to use lower total doses. In a study on patients with brain metastases 
cognitive decline was found already 4 months after WBRT with 30 Gy in 2.5 Gy single fractions (Chang et al. 
2009). In contrast, another trial on brain metastases using WBRT with 30 Gy yielded no cognitive decline and 
loss of QoL (Sun et al. 2011). Further reduced total doses of 23.4 Gy do not appear to have a strong detrimental 
effect on neurocognition in PCNSL patients (Correa et al. 2009). However, there is also no proof for a positive 
effect on overall survival conferred by dose-decreased WBRT (Ekenel et al. 2008; Shah et al. 2007). Another 
way of reducing neurotoxicity might be the technique of hippocampal sparing (Gondi et al. 2010). The true 
benefit of this technique for PCNSL patients has still to be shown. In the light of a lack of OS prolongation by 
WBRT, the best way to reduce the rate of late neurotoxicity is, however, to delay WBRT until 
progression/relapse as done in the no early WBRT arm of the G-PCNSL-SG-1 trial. This concept is also 
supported by observations of Hottinger and colleagues (2007) showing that the rate of neurotoxicity is reduced 
if the time interval between HD-MTX and WBRT is longer than 6 months.  
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In summary, the data from the G-PCNSL-SG-1 trial do not encourage to use consolidating WBRT as a part of 
first-line therapy of PCNSL: The omission of WBRT did not significantly shorten overall survival, and in 
addition, early WBRT was associated with a reduction of patients’ self-perceived quality of life and general 
cognitive function. Therefore, new concepts for consolidation therapy after HD-MTX based chemotherapy in 
PCNSL patients have to be explored. 
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Figure Captions and Tables 
 
Figure 1: Design of the G-PCNSL-SG-1 trial  
Abbreviations: WBRT = whole brain radiotherapy (45 Gy), HD-MTX = high-dose methotrexate, CR = complete 
response, PR = partial response, SD = stable disease, PD = progressive disease, HD-AraC = high-dose 
cytarabine 
* since 08/2006 combined with ifosfamide 1.5 g/m2daily, d3-5 
 
Figure 2: Time course of median scores and interquartile ranges (IQR) for EORTC-QLQ-C30 and BN20 
dimensions and the Mini Mental State Examination (MMSE) in the “early whole brain radiotherapy (WBRT)” 
arm and the “no early WBRT” arm of the G-PCNSL-SG-1 trial. P values (Mann-Whitney-U test) for 
comparisons between the arms in year 2 after randomization are inserted, *p<0.05. 
(A) Selected functional scores: global health, cognitive functioning, social functioning and emotional 
functioning. Higher values mean high functional status with less impairment in quality of life. Further functional 
scores are shown in Supplementary figure 1A. 
 (B) Selected symptom scores: communication deficit, fatigue, appetite loss and hair loss: Higher values mean a 
higher symptom burden with higher negative impact on quality of life. Further symptom scores are shown in 
Supplementary figure 1B. 
(C) Mini Mental State Examination (MMSE).  
 
Table 1: Patients’ characteristics in patients evaluable for quality of life (item “global health status”) at baseline 
and in year 2. There were no overt differences between the two arms. Data are median (IQR) or number (%). 
For further details see Thiel and colleagues (2010).   
a No early WBRT-arm (n=164) and early WBRT-arm (n=154) 
b 45% of per-protocol population 
c 45% of per-protocol population 
d 48% of patients alive 2 years after randomization 
e 42% of patients alive 2 years after randomization 
f Population eligible for MMSE analysis n=107 (65% of per-protocol population) 
g Population eligible for MMSE analysis n=98 (64% of per-protocol population) 
16 
 
 
Table 2: Mean change per year according to the mixed model longitudinal analysis (transformed scale of values 
between 0 and 100). For symptom scales, a negative value signifies a reduction of symptoms (improvement of 
QoL); for function scales, a negative value signifies a reduction in function (worsening of QoL). 
Abbreviations: WBRT = whole brain radiotherapy; KPS = Karnofsky Performance Score; MMSE = Mini 
Mental State Examination 
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Supplementary Material 
 
Supplementary figure 1: Time course of median scores and interquartile ranges for EORTC-QLQ-C30 and 
BN20 dimensions in the “early whole brain radiotherapy (WBRT)” arm and the “no early WBRT” arm of the G-
PCNSL-SG-1 trial. Selected scores have been included in figure 2A and 2B; supplementary figure 1 presents the 
remaining functional and symptom scores 
(A) Functional scores: physical functioning and role functioning. Higher values mean high functional status with 
less impairment in quality of life. P values (Mann-Whitney-U test) for comparisons between the arms in year 2 
after randomization are inserted.  
(B) Symptom scores: Diarrhea, nausea and vomiting, insomnia, constipation, dyspnea, financial difficulties, 
pain, future uncertainty, motor dysfunction, visual disorder, bladder control, drowsiness, itchy skin, headaches, 
seizures, weakness of legs. Higher values mean a higher symptom burden with higher negative impact on 
quality of life. P values (Mann-Whitney-U test) for comparisons between the randomization groups in year 2 
after randomization are inserted.  
 
Supplementary figure 2: Overall survival in both treatment arms of the cohort of patients evaluable for QoL at 
baseline (A) and in year 2 (B). 
 
  Per‐protocol 
population 
Population eligible for QoL‐analysis 
at baseline 
Population eligible for QoL‐analysis 
at 2 years 
  n=318a 
 
n=74b               
(no early WBRT) 
n=70c                
(early WBRT) 
n=37d 
(no early WBRT) 
n=33e               
(early WBRT) 
Age (years) 
    < 60 
    ≥ 60 
61 (53‐68) 
140 (44%) 
178 (56%) 
61 (55‐66) 
32 (43%) 
42 (57%) 
61 (51‐67) 
33 (47%) 
37 (53%) 
57 (49‐64) 
21 (57%) 
16 (43%) 
57 (50‐68) 
19 (58%) 
14 (42%) 
Sex 
    Male 
    Female 
 
183 (58%) 
135 (42%) 
 
39 (53%) 
35 (47%) 
 
30 (43%) 
40 (57%) 
 
22 (59%) 
15 (41%) 
 
20 (61%) 
13 (39%) 
Karnofsky performance score  80 (60‐90)  80 (60‐90)  80 (70‐90)  80 (60‐90)  80 (70‐90) 
Global health  ‐  50 (33‐60)  50 (33‐75)   ‐    ‐  
MMSE  ‐  26 (22‐29)f  27 (23‐29)g   ‐    ‐  
 
 Mean change/year  
Dimension No early WBRT Early WBRT p-value (ANOVA) 
BN20    
Future uncertainty +1.36 +4.83 0.02 
Visual disorder -1.58 +3.21 <0.01 
Motor dysfunction +4.37 +3.78 0.78 
Communication deficit -0.08 +2.93 0.03 
Headaches -1.62 +1.12 0.07 
Seizure deterioration -0.67 -0.27 0.72 
Drowsiness -0.06 +4.28 0.02 
Hair loss +0.99 +2.84 0.28 
Itchy skin +1.40 +5.75 0.03 
Weakness of legs -0.40 +4.86 <0.01 
Bladder control -0.21 +1.83 0.18 
C30    
Physical functioning +0.38 -2.97 0.03 
Role functioning -0.29 -6.11 0.02 
Emotional functioning +1.54 -1,74 0.02 
Cognitive functioning -1.06 -4.48 0.01 
Social functioning +2.01 -3.13 <0.01 
Global health status +1.74 -0.51 0.09 
Fatigue -1.01 +2.5 0.02 
Nausea/vomiting -1.80 -0.36 0.18 
Pain -0.37 +2.94 0.04 
 Dyspnoea -0.10 +1.29 0.36 
Insomnia -1.62 +2.73 0.02 
Appetite loss -1.48 +2.31 0.03 
Constipation +1.59 +1.13 0.77 
Diarrhoe +1.31 +0.32 0.33 
Financial difficulties +1.59 +4.55 0.08 




